KEYNOTE-671: Randomized, double-blind, phase 3 study of pembrolizumab or placebo plus platinum-based chemotherapy followed by resection and pembrolizumab or placebo for early stage NSCLC.

被引：0

作者：

Wakelee, Heather A.

Liberman, Moishe

Kato, Terufumi

Tsuboi, Masahiro

Lee, Se-Hoon

He, Jie

Gao, Shugeng

Chen, Ke-Neng

Dooms, Christophe Alfons

Majem, Margarita

Eigendorff, Ekkehard

Martinengo, Gaston Lucas

Bylicki, Olivier

Rodriguez-Abreu, Delvys

Chaft, Jamie E.

Novello, Silvia

Yang, Jing

Keller, Steven M.

Samkari, Ayman

Spicer, Jonathan

机构：

[1] Stanford Univ, Stanford Canc Inst, Div Oncol, Dept Med, Stanford, CA USA

[2] Ctr Hosp Univ Montreal, Montreal, PQ, Canada

[3] Kanagawa Canc Ctr, Yokohama, Kanagawa, Japan

[4] Natl Canc Ctr Hosp East, Kashiwa, Chiba, Japan

[5] Sungkyunkwan Univ, Div Hematol Oncol, Dept Internal Med, Samsung Med Ctr,Sch Med, Seoul, South Korea

[6] Chinese Acad Med Sci & Peking, Natl Canc Ctr, Natl Clin Res Ctr Canc, Canc Hosp, Beijing, Peoples R China

[7] Chinese Acad Med Sci & Pek, Dept Thorac Surg, Natl Clin Res Ctr Canc, Canc Hosp,Natl Canc Ctr, Beijing, Peoples R China

[8] Beijing Canc Hosp, Beijing, Peoples R China

[9] Univ Hosp Leuven, Leuven, Belgium

[10] Hosp Santa Creu & Sant Pau, Dept Med Oncol, Barcelona, Spain

[11] Zentralklin Bad Berka GmbH, Bad Berka, Germany

[12] Sanatorio Parque, Santa Fe, Argentina

[13] HIA SAINTE ANNE, Toulon, France

[14] Complejo Hosp Univ Insular Materno Infantil, Las Palmas Gran Canaria, Spain

[15] Mem Sloan Kettering Canc Ctr, New York, NY USA

[16] Univ Turin, AOU San Luigi Orbassano, Turin, Italy

[17] Merck & Co Inc, Rahway, NJ USA

[18] Merck & Co Inc, Kenilworth, NJ USA

[19] McGill Univ, Ctr Hlth, Montreal, PQ, Canada

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 17期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

LBA100

引用

页数：1

共 50 条

[41] KEYNOTE-826: Final overall survival results from a randomized, double-blind, phase 3 study of pembrolizumab plus chemotherapy vs placebo plus chemotherapy for first-line treatment of persistent, recurrent, or metastatic cervical cancer
Monk, Bradley J.
Colombo, Nicoletta
Tewari, Krishnansu Sujata
Dubot, Coraline
Caceres, M. Valeria
Hasegawa, Kosei
Shapira-Frommer, Ronnie
Salman, Pamela
Yanez, Eduardo
Gumus, Mahmut
de Mendoza, Mivael Olivera Hurtado
Samouelian, Vanessa
Castonguay, Vincent
Arkhipov, Alexander
Tekin, Cumhur
Li, Kan
Keefe, Stephen Michael
Lorusso, Domenica
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
[42] Phase 3, randomized, double-blind trial of pembrolizumab plus epacadostat or placebo for cisplatin-ineligible urothelial carcinoma (UC): KEYNOTE-672/ECHO-307.
Balar, Arjun Vasant
Plimack, Elizabeth R.
Grivas, Petros
Necchi, Andrea
De Santis, Maria
Pang, Lei
Keefe, Stephen Michael
O'Hayer, Kevin
Zhao, Yufan
De Wit, Ronald
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
[43] Pembrolizumab or Placebo With Chemoradiotherapy Followed by Pembrolizumab or Placebo for Newly Diagnosed, High-Risk, Locally Advanced Cervical Cancer (ENGOT-cx11/GOG-3047/KEYNOTE-A18): A Randomized, Double-Blind, Phase 3 Clinical Trial
Lorusso, Domenica
Xiang, Yang
Hasegawa, Kosei
Scambia, Giovanni
Leiva, Manuel
Ramos-Elias, Pier
Acevedo, Alejandro
Sukhin, Vladyslav
Cloven, Noelle
Gomes, Andrea J. Pereira de Santana
Mejia, Fernando Contreras
Reiss, Ari
Ayhan, Ali
Lee, Jung-Yun
Saevets, Valeriya
Zagouri, Flora
Gilbert, Lucy
Sehouli, Jalid
Tharavichitkul, Ekkasit
Lindemann, Kristina
Lazzari, Roberta
Chang, Chih-Long
Lampe, Rudolf
Zhu, Hong
Oaknin, Ana
Christiaens, Melissa
Polterauer, Stephan
Usami, Tomoka
Li, Kan
Yamada, Karin
Toker, Sarper
Keefe, Stephen M.
Pignata, Sandro
Duska, Linda R.
OBSTETRICAL & GYNECOLOGICAL SURVEY, 2024, 79 (09) : 523 - 524
[44] KEYNOTE-756: A Randomized, Double-blind, Phase 3 Study of Pembrolizumab or Placebo with Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy for High-Risk, Early-Stage, ER+/HER2-Breast Cancer
Hirshfield, Kim
Cardoso, Fatima
Bardia, Aditya
Andre, Fabrice
Cescon, David
McArthur, Heather
Telli, Melinda
Loi, Sherene
Cortes, Javier
Schmid, Peter
Harbeck, Nadia
Denkert, Carsten
Jackisch, Christian
Jia, Liyi
Karantza, Vassiliki
ANNALS OF SURGICAL ONCOLOGY, 2020, 27 (SUPPL 2) : S288 - S288
[45] KEYNOTE-811 pembrolizumab plus trastuzumab and chemotherapy for HER2+metastatic gastric or gastroesophageal junction cancer (mG/GEJC): A double-blind, randomized, placebo-controlled phase 3 study.
Janjigian, Yelena Yuriy
Bang, Yung-Jue
Fuchs, Charles S.
Qin, Shukui
Satoh, Taroh
Shitara, Kohei
Tabernero, Josep
Van Cutsem, Eric
Cao, Z. Alexander
Chen, Xinqun
Kang, S. Peter
Shih, Chie-Schin
Chung, Hyun Cheol
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
[46] Neoadjuvant pembrolizumab or placebo plus chemotherapy, followed by adjuvant pembrolizumab or placebo plus endocrine therapy for earlystage high-risk ER+/HER2-breast cancer: Results from the phase 3 KEYNOTE-756 study
Cardoso, F.
O'Shaughnessy, J.
McArthur, H.
Schmid, P.
Cortes, J.
Harbeck, N.
Telli, M. L.
Cescon, D. W.
Fasching, P.
Shao, Z.
Loirat, D.
Park, Y. H.
Gonzalez Fernandez, M.
Rubovszky, G.
Im, S. A.
Hui, R.
Takano, T.
Andre, F.
Yasojima, H.
Liu, Z.
Ding, Y.
Jia, L.
Karantza, V.
Tryfonidis, K.
Bardia, A.
EUROPEAN JOURNAL OF CANCER, 2024, 200 : 10 - 11
[47] ENGOT-ov65/KEYNOTE-B96: Phase 3, randomized, double-blind study of pembrolizumab versus placebo plus paclitaxel with optional bevacizumab for platinum-resistant recurrent ovarian cancer.
Colombo, Nicoletta
Coleman, Robert L.
Wu, Xiaohua
Kose, Fatih
Wenham, Robert Michael
Sebastianelli, Alexandra
Hasegawa, Kosei
Zsiros, Emese
Rouge, Thibault De la Motte
Bidzinski, Mariusz
McNeish, Iain A.
Sehouli, Jalid
Korach, Jacob
Debruyne, Philip R.
Kim, Jae-Weon
De Melo, Andrea C.
Peng, Xuan
Bogusz, Agata M.
Yamada, Karin Sayuri
Monk, Bradley J.
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
[48] Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial
Cortes, Javier
Cescon, David W.
Rugo, Hope S.
Nowecki, Zbigniew
Im, Seock-Ah
Yusof, Mastura Md
Gallardo, Carlos
Lipatov, Oleg
Barrios, Carlos H.
Holgado, Esther
Iwata, Hiroji
Masuda, Norikazu
Torregroza Otero, Marco
Gokmen, Erhan
Loi, Sherene
Guo, Zifang
Zhao, Jing
Aktan, Gursel
Karantza, Vassiliki
Schmid, Peter
LANCET, 2020, 396 (10265): : 1817 - 1828
[49] Pembrolizumab versus placebo as adjuvant therapy in completely resected stage IIB or IIC melanoma (KEYNOTE-716): a randomised, double-blind, phase 3 trial
Luke, Jason J.
Rutkowski, Piotr
Queirolo, Paola
Del Vecchio, Michele
Mackiewicz, Jacek
Chiarion-Sileni, Vanna
de la Cruz-Merino, Luis
Khattak, Muhammad A.
Schadendorf, Dirk
Long, Georgina, V
Ascierto, Paolo A.
Mandala, Mario
De Galitiis, Federica
Haydon, Andrew
Dummer, Reinhard
Grob, Jean-Jacques
Robert, Caroline
Carlino, Matteo S.
Mohr, Peter
Poklepovic, Andrew
Sondak, Vernon K.
Scolyer, Richard A.
Kirkwood, John M.
Chen, Ke
Diede, Scott J.
Ahsan, Sama
Ibrahim, Nageatte
Eggermont, Alexander M. M.
LANCET, 2022, 399 (10336): : 1718 - 1729
[50] KEYNOTE-811 pembrolizumab plus trastuzumab and chemotherapy for HER2+metastatic gastric or gastroesophageal junction cancer (mG/GEJc): A double-blind, randomized, placebo-controlled phase III study
Chung, Hyun Cheol
Bang, Yung-Jue
Fuchs, Charles S.
Qin, Shukui
Satoh, Taroh
Shitara, Kohei
Tabernero, Josep
Van Cutsem, Eric
Alsina, Maria
Cao, Z. Alexander
Chen, Xinqun
Bhagia, Pooja
Shih, Chie-Schin
Janjigian, Yelena Yuriy
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (04)

← 1 2 3 4 5 →